

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's		Applicant Michael Buschle et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-3</i>		Other Art <i>See Page 3-10</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2003/0162738	08/28/03	Egyed et al.	514	44	12/06/02
	A2	5,663,153	09/02/97	Hutcherson et al.	514	44	06/06/95
	A3	5,683,864	11/04/97	Houghton et al.	435	5	07/07/92
	A4	5,723,335	03/03/98	Hutcherson et al.	435	375	09/11/96
	A5	6,037,135	03/14/00	Kubo et al.	435	7.24	11/29/93
	A6	6,150,087	11/21/00	Chien	435	5	05/18/95
	A7	6,413,517	07/02/02	Sette et al.	424	185.1	01/21/98

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	A 1973/2000	11/23/00	Austria	English
	B2	A 805/2001	05/21/00	Austria	English
	B3	EP 0 468 520	01/29/92	Europe	English
	B4	WO 00/11186	03/02/00	WIPO	English
	B5	WO 00/23105	04/27/00	WIPO	English
	B6	WO 00/31542	06/02/00	WIPO	English
	B7	WO 00/44775	08/03/00	WIPO	English
	B8	WO 01/17551	03/15/01	WIPO	English
	B9	WO 01/21189	03/29/01	WIPO	English
	B10	WO 01/24822	04/12/01	WIPO	English
	B11	WO 01/54719	08/02/01	WIPO	English
	B12	WO 01/72782	10/04/01	WIPO	English
	B13	WO 01/78767	10/25/01	WIPO	English

25766598.1

EXAMINER:	/E.L./	DATE CONSIDERED:	08/07/2008
-----------	--------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's		Applicant Michael Buschle <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B14	WO 01/93903	12/13/01	WIPO	English
	B15	WO 01/93905	12/13/01	WIPO	English
	B16	WO 02/053185	07/11/02	WIPO	English
	B17	WO 02/095027	11/28/02	WIPO	English
	B18	WO 02/13857	02/21/02	WIPO	English
	B19	WO 02/32451	04/25/02	WIPO	English
	B20	WO 02/33127	04/25/02	WIPO	English
	B21	WO 03/047602	06/12/03	WIPO	English
	B22	WO 03/073097	09/04/03	WIPO	English
	B23	WO 2004/014936	02/19/04	WIPO	French (English Abstract)
	B24	WO 2004/024182	03/25/04	WIPO	English
	B25	WO 92/03458	03/05/92	WIPO	English
	B26	WO 93/00365	01/07/93	WIPO	English
	B27	WO 94/20127	09/15/94	WIPO	English
	B28	WO 94/25601	11/10/94	WIPO	English
	B29	WO 95/12766	05/11/95	WIPO	English
	B30	WO 95/22317	08/24/95	WIPO	English
	B31	WO 95/25122	09/21/95	WIPO	English
	B32	WO 95/27733	10/19/95	WIPO	English
	B33	WO 95/27901	10/19/95	WIPO	English
	B34	WO 96/02555	02/01/96	WIPO	English
	B35	WO 97/30721	08/28/97	WIPO	German (English Abstract)
	B36	WO 98/15287	04/16/98	WIPO	English

25766598.1

EXAMINER: /E.L./	DATE CONSIDERED: 08/07/2008
------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's		Applicant Michael Buschle et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page I-3</i>	Other Art <i>See Page 3-10</i>	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B37	WO 98/16247	04/23/98	WIPO	English
	B38	WO 98/18810	05/07/98	WIPO	English
	B39	WO 98/37919	09/03/98	WIPO	English
	B40	WO 98/40100	09/17/98	WIPO	English
	B41	WO 98/52581	11/26/98	WIPO	English
	B42	WO 98/52962	11/26/98	WIPO	English
	B43	WO 99/15259	04/01/99	WIPO	English
	B44	WO 99/33488	06/08/99	WIPO	English
	B45	WO 99/38528	08/05/99	WIPO	German (English Abstract)
	B46	WO 99/51259	10/14/99	WIPO	English
	B47	WO 99/56755	11/11/99	WIPO	English
	B48	WO 99/63941	12/16/99	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	"Aluminiumhydroxide," Röempp, 10 th Ed., pp. 139-140, 2006 (in German).
	C2	Anthony <i>et al.</i> , "Comprehensive determinant mapping of the hepatitis C-specific CD8 cell repertoire reveals unpredicted immune hierarchy," <i>Clinical Immunology</i> , 103(3):264-276, 2002.
	C3	Battegay <i>et al.</i> , "Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules," <i>J. Virol.</i> , 69(4):2462-2470, 1995.
	C4	Bellentani <i>et al.</i> , "Epidemiology of hepatitis C virus infection in Italy: the slowly unraveling mystery," <i>Microbes Infect.</i> , 2(14):1757-63, 2000.
	C5	Bitmansour <i>et al.</i> , "Clonotypic structure of the human CD4+ memory T cell response to cytomegalovirus," <i>J Immunol</i> , 167:1151-1163, 2001.

25766598.1

EXAMINER:	/E.L./	DATE CONSIDERED:	08/07/2008
-----------	--------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's		Applicant Michael Buschle et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C6	Blake <i>et al.</i> , "Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes," <i>J. Exp. Med.</i> , 184:121-130, 1996.
	C7	Britt and Alford, "Cytomegalovirus," In: <i>Fields Virology</i> by Fields <i>et al.</i> eds., Livincott-Raven, 2493-2523 1999.
	C8	Bullock <i>et al.</i> "Initiation codon scanthrough verses termination codon readthrough demonstrates strong potential for MHC class I restricted cryptic epitope expression," <i>Journal of Experimental Medicine</i> , 186:1051-1058, 1997.
	C9	Chang <i>et al.</i> , "Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C," <i>J. Immunol.</i> , 162:1156-1164, 1999.
	C10	Chen <i>et al.</i> , "A novel influenza A virus mitochondrial protein that induces cell death,: <i>Nature Medicine</i> , 7:1306-1312, 2001.
	C11	Chen <i>et al.</i> , "Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Bar virus-transformed B-lymphoblastoid cell lines to CD4 ⁺ T cells," <i>Journal of Virology</i> , 72(10):8301-8308, 1998.
	C12	Cho <i>et al.</i> , "Activation of human neutrophils by a synthetic anti-microbial peptide, KLKLLLLLK-NH2, via cell surface calreticulin," <i>Eur. J. Biochem.</i> , 266:878-885, 1999.
	C13	Cox <i>et al.</i> , "Identification of a peptide recognized by five melanoma-specific human cytotoxic t cell lines," <i>Science</i> , 264:716-719, 1994.
	C14	Di Bisceglie <i>et al.</i> , "New therapeutic strategies for hepatitis C," <i>Hepatology</i> , 35:224-231, 2002.
	C15	Diepolder <i>et al.</i> , "Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection," <i>J. Virol.</i> , 71(8):6011-6019, 1997.
	C16	Drew and Lalezari, "Cytomegalovirus: disease syndromes and treatment," <i>Curr Clin Top Infect Dis</i> , 19:16-29, 1999.
	C17	Duenas-Carrera <i>et al.</i> , "Enhancement of the immune response generated against hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids," <i>Biotechnol. Appl. Biochem.</i> , 35:205-212, 2002.
	C18	Elliot <i>et al.</i> "Recognition of out-of-frame major histocompatibility complex class I-restricted epitopes in vivo," <i>European Journal of Immunology</i> , 26:1175-1179, 1996.

25766598.1

EXAMINER:	/E.L./	DATE CONSIDERED:	08/07/2008
-----------	--------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's		Applicant Michael Buschle et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C19	Farci and Purcell, "Clinical significance of hepatitis C virus genotypes and quasispecies," <i>Semin Liver Dis.</i> , 20(1):103-26, 2000.
	C20	Fleckenstein et al., "New ligands binding to the human leukocyte antigen class II molecule DRB+0101 based on the activity pattern of an undecapeptide library," <i>European Journal of Biochemistry</i> , 240:71-77, 1996.
	C21	Greten and Schneck, "Development and use of multimeric major histocompatibility complex molecules," <i>Clinical and Diagnostic Laboratory Immunology</i> , 9(2):216-220, 2002.
	C22	Gruener et al., "Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus," <i>J. Virol.</i> , 75:5550-5558, 2001.
	C23	Hammer et al., "Promiscuous and allel-specific anchors in HLA-DR-binding peptides," <i>Cell</i> , 74:197-203, 1993.
	C24	Heemels and Ploegh, "Generation, translocation and presentation of mhc class I-restricted peptides," <i>Annu Rev Biochem</i> , 64:463-491, 1995.
	C25	Heile et al., "Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates," <i>J. Virol.</i> , 74(15):6885-6892, 2000.
	C26	Hemmer et al., "Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology," <i>J. Immunol.</i> , 160:3631-3636, 1998.
	C27	Hemmer et al., "The use of soluble synthetic peptide combinatorial libraries to determine antigen recognition of T cells," <i>J. Peptide Res.</i> , 52:338-345, 1998.
	C28	HLA-prevalence studies, In: HLA 1998, (Gjertson and Terasaki, eds.) American Society for Histocompatibility and Immunogenetics, Lenexa, Kansas, pp. 103-263, 1998.
	C29	Hoffmann et al., "Mapping of Immunodominant CD4+ T Lymphocyte Epitopes of Hepatitis C Virus Antigens and Their Relevance During the Course if Chronic Infection," <i>Hepatology</i> , 21(3):632-638, 1995.
	C30	Hunziker et al., "In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus," <i>International Immunology</i> , 14(6):615-626, 2002.

25766598.1

EXAMINER:	/E.L./	DATE CONSIDERED:	08/07/2008
-----------	--------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's		Applicant Michael Buschle et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page I-3</i>		Other Art <i>See Page 3-10</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C31	Ibe <i>et al.</i> , "Identification and characterization of a cytotoxic T cell epitope of hepatitis C virus presented by HLA-B*3501 in acute hepatitis," <i>J. Gen. Virol.</i> , 79:1735-1744, 1998.
	C32	Inchauspe and Feinstone, "Development of a hepatitis C virus vaccine," <i>Clinics in Liver Disease</i> , 7:243-259, 2003.
	C33	Keilholz <i>et al.</i> , "Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy," <i>J Immunother.</i> , 25(2):97-138, 2002.
	C34	Kern <i>et al.</i> , "Analysis of cd8 t cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides," <i>Eur J Immun</i> , 30:1676-1682, 2000.
	C35	Kern <i>et al.</i> , "Target structures of the cd8+-t-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited," <i>J Virol</i> , 73:8179-8184, 1999.
	C36	Klein, <i>Natural History of the MHC</i> , John Wiley and Sons, 1986.
	C37	Komanduri <i>et al.</i> , "Restoration of cytomegalovirus-specific cd4+ t-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1," <i>Nat Med</i> , 4:953-956, 1998.
	C38	Koziel <i>et al.</i> , "Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV," <i>J. Virol.</i> , 67:7522-7532, 1993.
	C39	Koziel <i>et al.</i> , "HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release," <i>J. Clin. Invest.</i> , 96:2311-2321, 1995.
	C40	Kurokohchi <i>et al.</i> , "A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection," <i>J. Hepatology</i> , 34:930-935, 2001.
	C41	Kwok <i>et al.</i> , "Rapid epitope identification from complex class-II-restricted T-cell antigens," <i>Trends in Immunology</i> , 22(11):583-588, 2001.
	C42	Lamontaca <i>et al.</i> , "Conserved Hepatitis C Virus Sequences Are Highly Immunogenic for CD4+ T Cells: Implications for Vaccine Development," <i>Hepatology</i> , 30(4):1088-1098, 1999.
	C43	Lauer <i>et al.</i> , "Comprehensive analysis of CD8 ⁺ -T-cell responses against hepatitis C virus reveals multiple unpredicted specificities," <i>Journal of Virology</i> , 76(12):6104-6113, 2002.
	C44	Lechmann and Liang, "Vaccine development for hepatitis C," <i>Seminars in Liver Disease</i> , 20:211-226, 2000.

25766598.1

EXAMINER:	/E.L./	DATE CONSIDERED:	08/07/2008
-----------	--------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's		Applicant Michael Buschle et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C45	Leroux-Roels <i>et al.</i> , "Lymphoproliferative Responses to Hepatitis C Virus Coes, E1, E2, and NS3 in Patients With Chronic Hepatitis C Infection Treated With Interferon Alfa," <i>Hepatology</i> , 23(1):8-16, 1996.
	C46	Liang <i>et al.</i> , "Pathogeneis, Natural History, Treatment, and Prevention of Hepatitis C," <i>Ann Intern Med.</i> , 132(4):296-305, 2000.
	C47	Maecker <i>et al.</i> , "Use of overlapping peptide mixtures as antigens for cytokine flow cytometry," <i>J Immunol Methods</i> , 255:27-40, 2001.
	C48	Malarkannan <i>et al.</i> , "Presentation of out-of-frame peptide/MHC class I complexes by a novel translation initiation mechanism," <i>Immunity</i> , 10:681-690, 1999.
	C49	Maynard <i>et al.</i> "An alternative translation reading frame encodes an immunodominant retroviral CTL determinant expressed by an immunodeficiency-causing retrovirus," <i>J. of Immunology</i> , 160:39-50, 1998.
	C50	Maynard <i>et al.</i> "Non-traditionally derived CTL epitopes: exceptions that prove the rules?" <i>Immunology Today</i> , 19:551-556, 1998.
	C51	McCluskie <i>et al.</i> , "Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA," <i>Fems Immunol and Medical Microbiol</i> , 32:179-185, 2002.
	C52	Morgan <i>et al.</i> , "The influence of exogenous peptide on beta2-microglobulin exchange in the HLA complex: analysis in real time," <i>Immunogenetics</i> , 48:98-107, 1998.
	C53	Nakajima <i>et al.</i> , "Chemotherapeutic activity of synthetic antimicrobial peptides: correlation between chemotherapeutic activity and neutrophil-activating activity," <i>FEBS Lett.</i> , 415:64-66, 1997.
	C54	Novak <i>et al.</i> , "Tetramer-guided epitope mapping: rapid identification and characterization of immunodominant CD4 ⁺ T cell epitopes from complex antigens," <i>The Journal of Immunology</i> , 166:6665-6670, 2001.
	C55	Parker <i>et al.</i> , "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains," <i>J. Immunol.</i> , 152:163, 1994.
	C56	Plotkin, "Vaccination against cytomegalovirus, the changeling demon," <i>Pediatr Infect Dis J</i> , 18:313-325, 1999.

25766598.1

EXAMINER:	/E.L./	DATE CONSIDERED:	08/07/2008
-----------	--------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's		Applicant Michael Buschle et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C57	Rammensee <i>et al.</i> , "SYFPEITHI: database for MHC ligands and peptide motifs," <i>Immunogenetics</i> , 50:213-219, 1999.
	C58	Reddehase, "The immunogenicity of human and murine cytomegaloviruses," <i>Curr Opin Immunol</i> , 12:390-396, 2000.
	C59	Rehermann <i>et al.</i> , "Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients," <i>J. Virol.</i> , 70(10):7092-7102, 1996.
	C60	Rollier <i>et al.</i> , "Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response," <i>J. Virol.</i> , 78(1):187-196, 2004.
	C61	Sarobe <i>et al.</i> , "Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions," <i>J. Clin. Invest.</i> , 102(6):1239-1248, 1998.
	C62	Shastri <i>et al.</i> , "Major histocompatibility class I molecules can present cryptic translation products to T-cells," <i>J. Biol. Chem.</i> 270:1088-1091, 1995.
	C63	Shirai <i>et al.</i> , "An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans," <i>J. Virol.</i> , 68(5):3334-3342, 1994.
	C64	Smith <i>et al.</i> , "Peptide sequences binding to MHC class II proteins," <i>Molecular Immunology</i> , 31:1431-1437, 1994.
	C65	Stern and Wiley, "Antigenic peptide binding by class I and class II histocompatibility proteins," <i>Structure</i> , 2:245-251, 1994
	C66	Stevens <i>et al.</i> , "Efficient generation of major histocompatibility complex class I-peptide complexes using synthetic peptide libraries," <i>Journal of Biological Chemistry</i> , 273:2874-2884, 1998.
	C67	Sturniolo <i>et al.</i> , "Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices," <i>Nature Biotechnology</i> , 17:555-562, 1999.
	C68	Tana <i>et al.</i> , "An HLA-binding-motif-aided peptide epitope library: a novel library design for the screening of HLA-DR4-restricted antigenic peptides recognized by CD4+ T cells," <i>J Hum Genet</i> , 43:14-21, 1998.

25766598.1

EXAMINER:	/E.L./	DATE CONSIDERED:	08/07/2008
-----------	--------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's		Applicant Michael Buschle et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page I-3</i>	Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C69	Thursz <i>et al.</i> , "Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research," <i>Lancet</i> , 354(9196):2119-24, 1999.
	C70	Tobery <i>et al.</i> , "A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified elispot assay," <i>J Immunol Methods</i> , 254:59-66, 2001.
	C71	Tourdot <i>et al.</i> , "A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes," <i>Eur. J. Immunol.</i> 30:3411-3421, 2000.
	C72	Van den Eynde and van der Bruggen, "T cell defined tumor antigens," <i>Curr Opin Immunol</i> , 5:684-693, 1997.
	C73	Varaklioti <i>et al.</i> , "Alternative translation occurs within the core coding region of the hepatitis C viral genome," <i>The Journal of Biological Chemistry</i> , 227:17713-17721, 2002.
	C74	Vernacchio <i>et al.</i> , "Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumococcal-CRM197 conjugate vaccine in healthy toddlers," <i>Vaccine</i> , 20(31-32):3658-67, 2002.
	C75	Villadangos and Ploegh, "Proteolysis in mhc class II antigen presentation: who's in charge," <i>Immunity</i> , 12:233-239, 2000.
	C76	Waldrop <i>et al.</i> , "Normal human cd4+ memory t cells display broad heterogeneity in their activation threshold for cytokine synthesis," <i>J Immunol</i> , 161:5284, 1998.
	C77	Walewski <i>et al.</i> , "Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame," <i>RNA</i> , 7:710-721, 2001.
	C78	Wang <i>et al.</i> , "Sequence variation in the gene encoding the nonstructural 3 protein of hepatitis C virus: evidence for immune selection," <i>J. Mol. Evol.</i> , 54:456-473, 2002.
	C79	Ward <i>et al.</i> , "Cellular immune responses against hepatitis C virus: the evidence base 2002," <i>Clin Exp Immunol.</i> , 128(2):195-203, 2002.
	C80	Weekes <i>et al.</i> , "Human CD28-CD28+ T cells contain greatly expanded functional virus-specific memory CTL clones," <i>J. Immunol</i> , 162:7569-7577, 1999.

25766598.1

EXAMINER:	/E.L./	DATE CONSIDERED:	08/07/2008
-----------	--------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's		Applicant Michael Buschle et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C81	Weekes <i>et al.</i> , "The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo," <i>J. Virol.</i> , 73(3):2099-2108, 1999.
	C82	Weiner <i>et al.</i> , "Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant," <i>Proc Natl Acad Sci U S A.</i> , 92(7):2755-9, 1995.
	C83	Wentworth <i>et al.</i> , "Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome," <i>Int. Immunol.</i> , 8(5):651-659, 1996.
	C84	Wilson <i>et al.</i> , "Immunogenicity. I. Use of peptide libraries to identify epitopes that activate clonotypic CD4+ T cells and induce T cell responses to native peptide ligands," <i>J. Immunol.</i> , 163:6424-6434, 1999.
	C85	Wolfel <i>et al.</i> , "Isolation of naturally processed peptides recognized by cytolytic t lymphocytes(ctl) on human emlanoma cells in association with hla-a2.1," <i>Int. J. Cancer</i> , 57:413-419, 1994.
	C86	Wong <i>et al.</i> , "Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all tranlated proteins of HCV," <i>Journal of Virology</i> , 75(3):1229-1235, 2001.
	C87	Wong <i>et al.</i> , "Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection," <i>J. Immunol.</i> , 160:1479-1488, 1998.
	C88	Xu <i>et al.</i> , "Synthesis of a novel hepatitis C virus protein by ribosomal frameshift," <i>The EMBO Journal</i> , 20:3840-3848, 2001.
	C89	Zaia <i>et al.</i> , "Cytomegalovirus prevention and treatment in 2000," <i>Hematology</i> , 339-355, 2000.

25766598.1

EXAMINER:	/Emily Le/	DATE CONSIDERED:	08/07/2008
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./